Champions Oncology, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Champions Oncology, Inc. engages primarily in the development and provision of advanced oncology-focused living tumor tissue models for drug development and personalized medicine. The company offers a comprehensive suite of products and services that include patient-derived xenograft (PDX) models, oncology drug screening services, precision oncology platforms, and proprietary tumor avatars used for therapeutic testing and biomarker discovery. Its key product categories encompass live tumor tissue models for preclinical research, cancer patient tumor-derived avatars for personalized treatment decision-making, and computational oncology solutions supporting drug efficacy predictions. Founded in 2007 and headquartered in Hackensack, New Jersey, Champions Oncology operates extensively across the United States and serves pharmaceutical, biotechnology companies, and clinical oncology researchers globally. The company is recognized for its innovative use of human tumor models that closely replicate individual patient tumors, enabling more predictive cancer drug development and tailored therapeutic strategies. Recent major developments for Champions Oncology include strategic partnerships enhancing its precision oncology platforms, expansion of its tumor avatar capabilities, and new collaborations aimed at integrating advanced AI and machine learning technologies for improved cancer treatment predictions. These initiatives reflect a significant push toward broadening its service offerings and reinforcing its position in the precision medicine landscape for oncology within the last 1-2 years. Overall, Champions Oncology operates within the biotechnology and pharmaceutical industries, focusing on oncology research tools and personalized medicine services, targeting pharmaceutical developers and clinical researchers dedicated to cancer therapeutics advancement. The company leverages its proprietary technologies to support drug development pipelines and individual patient treatment optimization, solidifying its role as a key actor in oncology-focused biotechnology solutions.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Champions Oncology Reports Revenue of $16.6 Million
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Market Today: Ford axes Lightning, iRobot bankrupt, Nvidia-China chips
Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi
Dow Settles Lower But Records Weekly Gain: Investor Sentiment Declines, Greed Index Moves To 'Fear' Zone
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025
Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Champions Oncology Reports Record Annual Revenue of $57 Million
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
Champions Oncology Announces Appointment of New CEO